Carey Thomas D. 4

What Happened

Carey Thomas D., a director of Standard BioTools, received equity awards on June 18, 2026 totaling 363,000 shares: 99,116 shares reported as shares acquired and 263,884 reported as derivative awards. Both grants were recorded at $0.00 per share (common for restricted stock units/awards), so the Form 4 shows $0 cash paid at grant. These are awards (transaction code A), not open-market purchases or sales.

Key Details

• Transaction date: June 18, 2026; Report filed: June 23, 2026 (filing is timely given the Juneteenth holiday on June 19).
• Price: $0.00 per share (award/RSU grant).
• Total shares granted: 99,116 (direct) + 263,884 (derivative) = 363,000.
• Shares owned after transaction: Not specified in the information provided in this summary (not reported here).
• Footnotes:
  • F1: The 263,884 units represent Restricted Stock Units (RSUs) that vest in full on the earlier of June 18, 2027 and one day prior to the Company's next annual meeting, subject to continued service. Each RSU converts to one share upon vesting.
  • F2: Notes an option vesting schedule — "the Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026" — but no option exercise or option grant transaction is reported in the items summarized here.

Context

• These awards are grants/RSUs (future-delivery rights to shares) and do not represent an immediate cash purchase or sale; economic value depends on the stock price at vesting.
• Awards to directors are common as compensation and do not by themselves indicate insider sentiment about near-term stock performance.
• For retail investors, purchases (cash buys) are often viewed as stronger direct signals than grants; this filing is a compensation award rather than a market buy or sell.